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Abstract 
Background: Although previous studies have evaluated the effect of anti-VEGF therapies for central retinal vein 
occlusion (CRVO) patients, the majority of previous studies have excluded or included a very small number of patients 
with ischemic CRVO (iCRVO). The aim of our study is to examine the effects of bevacizumab on macular edema 
secondary to ischemic central retinal vein occlusion, as well as the effects on central choroidal thickness and best-
corrected visual acuity.
Methods: In this prospective, interventional case series, iCRVO was defined by the presence of ≥ 10 or more disc 
diameter areas of retinal nonperfusion by fluorescein angiography (FA) and by the presence of a b/a ratio less than 
1.5 by full-field electroretinogram (ffERG). Nine eyes with iCRVO received monthly bevacizumab 0.5 mg injections 
at baseline and months 1 to 5 for a maximum of six injections. Main outcome measures were visual acuity (Snellen), 
central foveal thickness, and central choroidal thickness as measured by Spectral-Domain Optical Coherence Tomog-
raphy (SD-OCT) at baseline and at 6 month following initial intravitreal bevacizumab injection. Pairwise t-tests and the 
Wilcoxon signed-rank test were conducted to compare the outcome measures.
Results: After intravitreal administration of bevacizumab, there was a significant reduction of central foveal thickness 
from 858 ± 311 μm at baseline to 243 ± 106 μm at the 6-month follow-up, as well as a significant reduction of central 
choroidal thickness from 282 ± 38 μm at baseline to 227 ± 56 μm at the 6-month follow-up (p = 0.0006, p = 0.0003 
respectively). The visual acuity worsened from a median of 1.3 to 1.7 (p = 0.02).
Conclusion: In patients with iCRVO, intravitreal bevacizumab led to a reduction of central macular edema and cen-
tral choroidal thickness, but a worsening of visual acuity. Intravitreal bevacizumab reduces macular edema but is not 
able to overcome the poor prognosis of iCRVO.
Keywords: Ischemic central retinal vein occlusion, Bevacizumab, Macular edema, Choroidal thickness
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Retinal vein occlusion (RVO) is the second most com-
mon blinding vascular disorder of the retina [1]. Previ-
ous studies have demonstrated that ischemic CRVO 
(iCRVO) confers a poorer prognosis than non-ischemic 
CRVO (non-iCRVO) [2, 3]. For example, patients with 
iCRVO have significantly higher levels of aqueous and 
vitreous vascular endothelial growth factor (VEGF) con-
centrations as compared to patients with non-iCRVO 
[4, 5]. The higher levels of VEGF in iCRVO play a role in 
development of neovascularization, which increases the 
risk for vision-threatening complications, such as vitre-
ous hemorrhage, neovascular glaucoma, and tractional 
retinal detachment [2, 6]. Even after sequalae secondary 
to CRVO resolve, iCRVO patients fare more poorly com-
pared to non-iCRVO patients [2].
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Intravitreal anti-VEGF drugs have become first-line 
therapy for patients with macular edema secondary to 
CRVO [7]. Many studies have successfully demonstrated 
the efficacy of anti-VEGF drugs in CRVO [8–14]. For 
example, the CRUISE randomized controlled trial dem-
onstrated that CRVO patients who received intravitreal 
ranibizumab injections had a significant reduction of 
central foveal thickness at 6-months as compared to the 
control group [8]. Similarly, Epstein et al. [9] conducted 
a randomized controlled trial that showed that patients 
who received intravitreal bevacizumab injections had 
best-corrected visual acuity BCVA that improved by 14.1 
ETDRS letters at 24 weeks compared with a decrease of 
2.0 letters in the control group.
While previous studies have shed light on the effect 
of anti-VEGF drugs for CRVO patients, the majority of 
previous studies have excluded or included a very small 
number of patients with iCRVO. For example, GALILEO 
found that aflibercept reduced macular edema secondary 
to CRVO, however, only 14 of the 177 patients included 
in the study had iCRVO and separate analysis for out-
comes of iCRVO patients was not conducted given the 
small number of patients [13]. In addition, CRYSTAL 
was a prospective study that showed that intravitreal 
ranibizumab injections for CRVO patients led to signifi-
cant improvement of visual acuity, with 63.8% of patients 
gaining ≥ 10 ETDRS (Early Treatment Diabetic Retin-
opathy Study) letters [14]. While 54 eyes had iCRVO in 
the CRYSTAL study, the definition was not given and the 
data specific to iCRVO and non-iCRVO patients was not 
provided separately, making it difficult to draw conclu-
sions specific to iCRVO patients [14]. In our prospective 
case series, we aim to describe the effect of intravitreal 
bevacizumab on macular edema secondary to CRVO, 




The current study was designed as a prospective case 
series and performed at the Ophthalmology Depart-
ment at the University of São Paulo Medical School dur-
ing 2012. The study was approved by the institutional 
review board and adhered to the tenets of the Declara-
tion of Helsinki. The inclusion criteria were as follows: 
(1) Diagnosis of ischemic CRVO by an ophthalmologist. 
Ischemia was defined by the presence of ≥ 10 or more 
disc diameter areas of retinal nonperfusion by fluores-
cein angiography (FA) and by the presence of a b/a ratio 
less than 1.5 by full-field electroretinogram (ffERG). (2) 
Age of 18  years or older. (3) Diagnosis of iCRVO up to 
6 months prior to study enrollment. (4) Baseline Snellen 
visual acuity worse than 20/200. Patients were excluded 
if they had presence of refractive error exceeding ± 6.00 
diopters (D) of spherical equivalent, presence of more 
than 2 diopters of keratometric astigmatism, axial length 
of more than 26.5 mm, important media opacity resulting 
in poor OCT image quality, prior history of CRVO, his-
tory of any retinal disease, including diabetic retinopathy, 
uveitis, glaucoma or any other optic neuropathy, intraoc-
ular surgery in the past 3  months (including cataract 
surgery), intravitreal injections (steroids and/or anti-vas-
cular endothelial growth factor) and/or laser treatment.
Study protocol
All patients underwent a comprehensive ocular exam-
ination, including visual acuity on Snellen chart, 
biomicroscopy of anterior and posterior segments, 
intraocular pressure, and Spectral-Domain Optical 
Coherence Tomography (SD-OCT) (Spectralis; Heidel-
berg Engineering, Heidelberg, Germany) and ffERG. The 
ffERG was performed compliant with the standards of 
the International Society for Clinical Electrophysiology of 
Vision (ISCEV). All procedures were performed at stand-
ardized visits at baseline, at 1, 2, 3, 4, 5 and 6  months, 
before each bevacizumab injection, with a time window 
of ± 2 weeks. FA and ffERG were performed only at base-
line as part of screening procedures.
Spectral-Domain Optical Coherence Tomography 
images were acquired using the automated eye alignment 
eye-tracking software (TruTrack; Heidelberg Engineer-
ing) to obtain 25 high-speed horizontal line scans of the 
macula of both eyes within the central 20° centered in 
the fovea. The central foveal thickness derived from the 
Early Treatment Diabetic Retinopathy Study (ETDRS) 
grid was selected as the outcome measure for evaluating 
the central macular edema (CME). SD-OCT with an EDI 
(enhanced depth imaging) protocol (horizontal and verti-
cal scans, 20 × 20, 49 sections, high resolution mode, 30 
frames) was also performed to obtain the central choroi-
dal thickness (CCT). CCT was measured at the subfoveal 
position. The CCT measures were performed manually 
using the caliper of the Eye Explorer Software (v. 6.0.9.0; 
Heidelberg Engineering), with 80% zoom. The measure 
was obtained perpendicularly, from the outer edge of the 
hyperreflective retinal pigmented epithelium (RPE) to the 
hyperreflective inner sclera. All SD-OCT images were 
routinely obtained at the same time, avoiding diurnal var-
iations of the choroidal and retinal thicknesses.
Injection protocol
Patients received their monthly bevacizumab 0.5  mg 
injection at baseline and months 1 to 5 for a maximum 
of six injections. Sterile protocol for intravitreal injection 
included the use of 5% povidone–iodine solution, topical 
anesthesia, eyelid-speculum application, and intravitreal 
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injection of 0.5 mg of bevacizumab via pars plana at the 
inferotemporal quadrant at 4  mm from the limbus in 
phakic eyes and 3.5 mm in pseudophakic eyes, followed 
by postoperative topical antibiotic eye drops.
Statistical analysis
All data collection and analyses were performed using 
MS-Excel 2018 (Microsoft Corporation, USA). Continu-
ous variables are presented as mean ± standard deviation 
or median (range). The primary outcome measures were: 
visual acuity, central foveal thickness and central choroi-
dal thickness. Pairwise t-tests and the Wilcoxon signed-
rank test were conducted to determine compare the 
outcome measures were statistically different between 
baseline and after treatment. p < 0.05 was considered 
significant.
Results
A total of nine individuals (five females) with iCRVO were 
enrolled in the study. Five patients identified as white 
(55.6%), 2 as hispanic (22.2%), and 2 as black (22.2%). 
Eight patients had hypertension (88.9%) and 1 patient 
had diabetes mellitus (1.1%). The age of the patients 
ranged from 44 to 78  years (mean, 57.9 ± 10.6  years). 
Duration of symptoms before treatment ranged from 1 to 
6 months (mean, 2.4 ± 1.6 months). All individuals com-
pleted the 6-month follow-up period and received all six 
intravitreal injections of bevacizumab. No patients expe-
rienced adverse events (endophthalmitis, retinal detach-
ment, lens trauma) due to injections during the study, 
however, one patient had a vitreous hemorrhage and 
another patient developed neovascular glaucoma dur-
ing the study period and despite intravitreal injections of 
bevacizumab. Table 1 shows the demographics and clini-
cal characteristics of patients included in the study.
After intravitreal administration of bevacizumab, there 
was a significant decrease in visual acuity from a median 
of 1.3 to 1.7 (p = 0.02). Prior to study treatment the visual 
acuity of eyes was: 1 eye with 20/200, 5 eyes with 20/400, 
2 eyes with 20/1000, and 1 eye with hand movements. At 
the 6-month follow-up the visual acuity of eyes was: 1 eye 
with 20/400, 6 eyes with 20/1000, 1 eye with hand move-
ments, and 1 eye with no light perception. For the pur-
poses of our study, visual acuity of hand movements was 
defined as 20/4000.
Following study treatment, all patients had a signifi-
cant decrease in both the central foveal thickness and 
central choroidal thickness. The mean central foveal 
thickness was 858 ± 311  μm at baseline and decreased 
to 243 ± 106  μm at the 6-month follow-up (p = 0.0006). 
The mean central choroidal thickness was 282 ± 38  μm 
at baseline and decreased 227 ± 56  μm at the 6-month 
time point (p = 0.0003). Figures 1 and 2 demonstrate the 
reduction of macular edema for two patients examined 
during the study (Table 2).  
Discussion
In our prospective case series, we evaluated the effect of 
intravitreal injections of bevacizumab on structural and 
functional outcome measures of patients with iCRVO. 
The results demonstrated after six consecutive bevaci-
zumab injections over a 6-month period, patients had a 
significant decrease in central foveal thickness and cen-
tral choroid thickness, however, significantly worse visual 
acuity. Patients did not have any drug-related complica-
tions during the study period.
Similar to our findings, previous studies have found 
that intravitreal injections of bevacizumab reduce cen-
tral macular edema for CRVO patients [9, 12, 15–17]. 
There are previous studies that have specifically exam-
ined the effect of anti-VEGF drugs in iCRVO patients. 
For example, the COPERNICUS randomized control trial 
demonstrated that at a 6-month follow-up, 51.4% of 29 
iCRVO eyes that received aflibercept gained > 15 letters 
as compared to 4.3% in the sham group [11]. The RAVE 
trial showed that iCRVO patients who received intravit-
real ranibizumab had a mean visual acuity gain of 21.4 
ETDRS letters at 36-months [11]. With the exception of 
Priglinger et al. [12] and Costa et al. [17], a major weak-
ness of previous studies is that they did not delineated 
between iCRVO and non-iCRVO patients. Prigliner et al. 
[12] conducted a prospective, consecutive, noncompara-
tive case series in which patients received an intravitreal 
injection of bevacizumab on day 1 and 4 weeks thereafter. 
Additional injections of bevacizumab were given within 
the 6-month study period if patients had not surpassed 
treatment success and did not meet criteria for treatment 
futility [12]. Treatment success was defined as BCVA of 
≥ 79 ETDRS letters and average central retinal thickness 
by OCT as ≤ 225 μm [12]. If treatment had been stopped, 
it was reinitiated if retinal thickness increased by ≥ 50 μm 
or BCVA was < 74 ETDRS letters [12]. Treatment futility, 
defined as not achieving at least a decrease 50 μm of aver-
age central retinal thickness and an increase of BCVA of 
≥ 5 letters [12]. The study found that the mean baseline 
of central retinal thickness significantly decreased from 
535 ± 148 to 323 ± 116 for all CRVO patients, and from 
534 ± 193 to 279 ± 127 for iCRVO patients [12]. Costa 
et  al. [17] conducted a prospective study over 25 weeks 
in which ischemic central and hemicentral RVO patients 
received an intravitreal injection of bevacizumab at base-
line every 12  weeks if macular edema recurrence was 
documented by OCT. The central macular thickness 
decreased from a baseline of 730.1  μm to 260.3  μm at 
























































































































































































































































































































































































Page 5 of 8Hall et al. Int J Retin Vitr            (2019) 5:32 
Fig. 1 Change in retinal thickness after intravitreal bevacizumab. A 78-year-old patient presented with ischemic central retinal vein occlusion, 
which is shown by fluorescein angiography (a, b). He had symptoms for 6 months. Baseline visual acuity was reduced to hand movements. Optical 
coherence tomography shows baseline (c) and at the 6-month follow-up shows macular edema has decreased, the foveal contour has been lost 
due to the presence of the epiretinal membrane, and there is degeneration of the outer retinal layers. Although the macular edema resolves, the 
final acuity was no light perception
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the 25-week follow-up [17]. Table 3 demonstrates a com-
parison of the outcomes of our study with the previously 
described studies.
Our study also found that intravitreal injections of 
bevacizumab lead to a reduction of central choroidal 
thickness in iCRVO patients. Previous studies have seen 
a reduction of CCT in patients with diabetic retinopa-
thy, and some postulate that this reduction is related to 
damage to the retina [18, 19]. The choroid is the primary 
source of oxygen and nutrition to the outer layers of the 
retina, and if the choroid is damaged from retinal tis-
sue hypoxia or ischemia such as diabetes mellitus, this 
could result in decreased blood supply to the outer retina 
and thus damage to photoreceptors. It is possible that a 
similar phenomenon occurs with anti-VEGF injections. 
Increased choroidal thickness has also been found to be 
associated with better visual acuity [20]. It is difficult to 
draw conclusions about the reduction of CCT, however, 
Fig. 2 Change in retinal thickness after intravitreal bevacizumab. A 48-year-old patient presented with intraretinal hemorrhages in the four 
quadrants ischemic, macular edema, vascular tortuosity compatible with central retinal vein occlusion, which is shown by fluorescein angiography 
(a, b). He had symptoms for 2 months. Baseline visual acuity was reduced to 20/200, and the baseline optical coherence tomography shows 
macular edema and serous retinal detachment (c). At the 6-month follow-up macular edema has decreased, the foveal contour has been recovered, 
and there is degeneration of the outer retinal layers
Table 2 Results for  nine cases of  ischemic central retinal 
vein occlusion
Data are presented as median (range) or mean ± standard deviation
HM hand movements, NLP no light perception
*Wilcoxon signed-rank test
# Pairwise t-test
Finding Baseline 6 months p value
Visual acuity, logMAR 1.3 (1 to HM) 1.7 (1.3 to NLP) 0.02*
Central foveal thickness 858 ± 311 243 ± 106 0.0006#
Central choroidal thickness 282 ± 38 227 ± 56 0.0003#
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future studies examining the effect of anti-VEGF agents 
could use CCT as an outcome measure given that the 
reduction of CCT has been found to be significantly cor-
related with reduction of macular edema [21, 22].
In contrast to the aforementioned studies, our study 
found no correlation between the structural and 
functional outcomes given that the visual acuity of 
patients significantly worsened. These findings could 
be explained by the poorer prognosis that iCRVO con-
fers as compared to non-iCRVO [2]. Although this 
study was not comparative, an observational study 
of untreated patients showed that after resolution of 
macular edema, final visual acuity was reported to be 
20/100 or better in 83% of non-iCRVO eyes as com-
pared to 12% in iCRVO eyes [2]. Moreover, the damage 
to photoreceptors caused by CRVO may persist despite 
resolution of macular edema, and therefore the reso-
lution of macular edema may not cause an improve-
ment of visual acuity in these cases of severe macular 
ischemia [22]. Future studies using OCT at the study 
endpoint may shed light on residual retinal ischemia 
and correlation to final visual acuity. In the long-term 
the visual acuity of CRVO worsens, as shown by the 
HORIZON trial, which found that despite receiving 
intravitreal injections of ranibizumab for a year, the vis-
ual acuity CRVO eventually declined [23]. Furthermore, 
the natural history of CRVO is variable [2, 3]. Addition-
ally, the Central Vein Occlusion Study found that the 
final visual acuity after CRVO is strongly linked to ini-
tial visual acuity, with only 19% of patients with initial 
visual acuity of worse than 20/200 having a final visual 
acuity of better than 20/200 [24]. Thus, an improve-
ment for this group of patients is rare. Our study only 
included patients with visual acuity of 20/200 or worse, 
all of whom had a worsening of visual acuity or main-
tained their initial poor visual acuity.
Strengths of our study include: the prospective nature, 
strict criteria for defining iCRVO using fluorescein angi-
ography and full-field electroretinogram, and a stand-
ardized protocol for imaging acquisition. In addition, 
patients did not receive any other form of treatment for 
CRVO, such as intravitreal corticosteroids. Finally, all 
patients received the same number of administrations of 
intravitreal bevacizumab every 4 weeks during a 6-month 
time period. Limitations of our study include the small 
sample size as well as the noncomparative nature of the 
study.
Our results suggest that patients that had received 
intravitreal bevacizumab treatment for iCRVO had 
reduction of central macular thickness and central cho-
roidal thickness but worsening of visual acuity. Patients 
with iCRVO may not necessarily benefit from intravit-
real bevacizumab injections as iCRVO confers a poorer 
prognosis as compared to non-iCRVO. Future studies are 
needed to ascertain the long-term effects of bevacizumab 
for iCRVO patients and to further examine the correla-
tion between structural and functional outcomes.
Conclusion
In patients with iCRVO, intravitreal bevacizumab led to 
a reduction of central macular edema and central choroi-
dal thickness, but a worsening of visual acuity. Intravit-
real bevacizumab reduces macular edema but is not able 
to overcome the poor prognosis of iCRVO.
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Baseline CFT, μm 6 month CFT, μm
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